Prelude Capital Management’s Sanara MedTech SMTI Stock Holding History

Prelude Capital Management’s Portfolio SMTI Stock Details SMTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,286	Closed	-$212K	–	1336
2023 Q2	$212K	Sell	5,286 -1,239	-19%	-$50.7K	0.01%	828
2023 Q1	$269K	Sell	6,525 -2,324	-26%	-$98K	0.02%	692
2022 Q4	$403K	Sell	8,849 -2,427	-22%	-$83.6K	0.02%	659
2022 Q3	$335K	Sell	11,276 -4,439	-28%	-$124K	0.01%	822
2022 Q2	$328K	Sell	15,715 -909	-5%	-$21.2K	0.01%	1019
2022 Q1	$473K	Sell	16,624 -599	-3%	-$15.2K	0.01%	891
2021 Q4	$509K	Buy	17,223 +4,300	+33%	+$135K	0.01%	992
2021 Q3	$443K	Sell	12,923 -2,643	-17%	-$94.8K	0.01%	954
2021 Q2	$575K	Buy	15,566 +5,081	+48%	+$149K	0.02%	872
2021 Q1	$327K	Buy	+10,485	New	+$363K	0.01%	1100

Other funds holding SMTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return

SIC

Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Prelude Capital Management's SMTI Position: Q3 2023 in Review

Prelude Capital Management sold out of Sanara MedTech (SMTI) in Q3 2023, closing a stake of 5,286 shares — an estimated $212K sold.

Prelude Capital Management first reported a position in SMTI in Q1 2021 and held it in 10 quarters. The position peaked at $575K in Q2 2021. 43 funds tracked by Wall St. Rank hold SMTI as of Q3 2023.

Prelude Capital Management reported no remaining Sanara MedTech position as of Q3 2023 after selling out during the quarter.
Prelude Capital Management sold 5,286 Sanara MedTech shares in Q3 2023, an estimated $212K.
Prelude Capital Management first reported a position in Sanara MedTech in Q1 2021 and held it in 10 quarters.
Prelude Capital Management's Sanara MedTech position peaked at $575K in Q2 2021.
43 funds tracked by Wall St. Rank held Sanara MedTech as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.